Akoya Biosciences (NasdaqGS:AKYA) - Share price, News & Analysis

AKYA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

AKYA Stock Overview

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research.

Rewards

Revenue is forecast to grow 21.17% per year

Revenue grew by 36.6% over the past year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Akoya Biosciences Competitors

Thermo Fisher Scientific

NYSE:TMO

US$214.8b

Illumina

NasdaqGS:ILMN

US$37.7b

Agilent Technologies

NYSE:A

US$37.3b

PerkinElmer

NYSE:PKI

US$18.2b

Price History & Performance

Summary of all time highs, changes and price drops for Akoya Biosciences
Historical stock prices
Current Share Price	US$9.92
52 Week High	US$22.15
52 Week Low	US$8.02
Beta	0
1 Month Change	-2.74%
3 Month Change	-0.50%
1 Year Change	-54.58%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-61.92%

Recent News & Updates

May 11

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

There's been a notable change in appetite for Akoya Biosciences, Inc. ( NASDAQ:AKYA ) shares in the week since its...

Shareholder Returns

	AKYA	US Life Sciences	US Market
7D	9.9%	-0.7%	-4.0%
1Y	-54.6%	-10.0%	-13.2%

Return vs Industry: AKYA underperformed the US Life Sciences industry which returned -8.8% over the past year.

Return vs Market: AKYA underperformed the US Market which returned -12.3% over the past year.

Price Volatility

Is AKYA's price volatile compared to industry and market?
AKYA volatility
AKYA Average Weekly Movement	12.4%
Life Sciences Industry Average Movement	10.7%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: AKYA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: AKYA's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	319	Brian McKelligon	https://www.akoyabio.com

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response. The company also provides PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen, or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

Akoya Biosciences Fundamentals Summary

How do Akoya Biosciences's earnings and revenue compare to its market cap?
AKYA fundamental statistics
Market Cap	US$372.89m
Earnings (TTM)	-US$51.20m
Revenue (TTM)	US$59.60m

6.3x

P/S Ratio

-7.3x

P/E Ratio

Is AKYA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AKYA income statement (TTM)
Revenue	US$59.60m
Cost of Revenue	US$22.69m
Gross Profit	US$36.91m
Other Expenses	US$88.11m
Earnings	-US$51.20m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.36
Gross Margin	61.93%
Net Profit Margin	-85.91%
Debt/Equity Ratio	30.6%

How did AKYA perform over the long term?

See historical performance and comparison

Valuation

Is Akoya Biosciences undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

3.5x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AKYA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AKYA's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: AKYA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Life Sciences industry average.

PE vs Market: AKYA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AKYA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: AKYA is overvalued based on its Price-To-Book Ratio (3.5x) compared to the US Life Sciences industry average (2.2x).

Future Growth

How is Akoya Biosciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

19.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKYA's revenue (21.2% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: AKYA's revenue (21.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AKYA is forecast to be unprofitable in 3 years.

Past Performance

How has Akoya Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-84.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: AKYA is currently unprofitable.

Growing Profit Margin: AKYA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AKYA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AKYA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKYA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).

Return on Equity

High ROE: AKYA has a negative Return on Equity (-48.1%), as it is currently unprofitable.

Financial Health

How is Akoya Biosciences's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AKYA's short term assets ($126.5M) exceed its short term liabilities ($31.7M).

Long Term Liabilities: AKYA's short term assets ($126.5M) exceed its long term liabilities ($48.8M).

Debt to Equity History and Analysis

Debt Level: AKYA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if AKYA's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKYA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AKYA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 62.3% each year.

Dividend

What is Akoya Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AKYA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AKYA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AKYA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKYA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AKYA has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure

CEO

Brian McKelligon (52 yo)

4.83yrs

Tenure

US$2,267,321

Compensation

Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...

CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD2.27M) is about average for companies of similar size in the US market ($USD2.59M).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AKYA's management team is considered experienced (3.8 years average tenure).

Board Members

Experienced Board: AKYA's board of directors are considered experienced (4.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31